Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Chemed Co. (NYSE:CHE - Free Report) by 36.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,406 shares of the company's stock after buying an additional 914 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Chemed were worth $1,804,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. CIBC Asset Management Inc lifted its holdings in shares of Chemed by 5.1% during the 4th quarter. CIBC Asset Management Inc now owns 457 shares of the company's stock valued at $242,000 after acquiring an additional 22 shares in the last quarter. EP Wealth Advisors LLC lifted its holdings in shares of Chemed by 1.9% during the 3rd quarter. EP Wealth Advisors LLC now owns 1,354 shares of the company's stock valued at $814,000 after acquiring an additional 25 shares in the last quarter. Argonautica Private Wealth Management Inc. lifted its holdings in shares of Chemed by 7.2% during the 4th quarter. Argonautica Private Wealth Management Inc. now owns 505 shares of the company's stock valued at $268,000 after acquiring an additional 34 shares in the last quarter. SRS Capital Advisors Inc. lifted its holdings in shares of Chemed by 39.2% during the 4th quarter. SRS Capital Advisors Inc. now owns 135 shares of the company's stock valued at $72,000 after acquiring an additional 38 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of Chemed by 11.5% during the 3rd quarter. KBC Group NV now owns 378 shares of the company's stock valued at $227,000 after acquiring an additional 39 shares in the last quarter. 95.85% of the stock is owned by hedge funds and other institutional investors.
Chemed Trading Down 1.2 %
CHE stock traded down $7.20 during trading on Friday, reaching $594.41. The stock had a trading volume of 355,669 shares, compared to its average volume of 88,890. Chemed Co. has a 1-year low of $512.12 and a 1-year high of $648.75. The company has a market capitalization of $8.70 billion, a P/E ratio of 30.04, a PEG ratio of 2.15 and a beta of 0.43. The firm has a fifty day moving average price of $566.29 and a 200 day moving average price of $565.60.
Chemed Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Monday, February 24th were given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 0.34%. The ex-dividend date was Monday, February 24th. Chemed's payout ratio is currently 10.05%.
Insider Transactions at Chemed
In related news, VP Brian C. Judkins bought 145 shares of the company's stock in a transaction dated Monday, December 30th. The stock was bought at an average price of $519.50 per share, with a total value of $75,327.50. Following the transaction, the vice president now owns 1,678 shares of the company's stock, valued at approximately $871,721. This trade represents a 9.46 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $593.67, for a total transaction of $1,187,340.00. Following the completion of the sale, the chief executive officer now directly owns 102,679 shares of the company's stock, valued at $60,957,441.93. The trade was a 1.91 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.32% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on CHE shares. StockNews.com upgraded shares of Chemed from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Royal Bank of Canada boosted their price objective on shares of Chemed from $633.00 to $667.00 and gave the stock an "outperform" rating in a report on Friday, March 14th.
Check Out Our Latest Stock Report on Chemed
Chemed Company Profile
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
See Also
Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
